PortfoliosLab logoPortfoliosLab logo
ITCI vs. HALO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ITCI vs. HALO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intra-Cellular Therapies, Inc. (ITCI) and Halozyme Therapeutics, Inc. (HALO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


ITCI

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

HALO

1D
5.34%
1M
8.13%
YTD
3.74%
6M
7.98%
1Y
30.97%
3Y*
27.65%
5Y*
12.08%
10Y*
21.91%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ITCI vs. HALO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ITCI
Intra-Cellular Therapies, Inc.
0.00%57.89%16.62%35.34%1.11%64.59%-7.32%201.23%-21.34%-4.04%
HALO
Halozyme Therapeutics, Inc.
3.74%40.77%29.36%-35.04%41.51%-5.85%140.89%21.19%-27.79%105.06%

Correlation

The correlation between ITCI and HALO is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (3Y)
Calculated over the trailing 3-year period

0.11

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Jan 8, 2014

0.34

The correlation between ITCI and HALO shifts across timeframes, from 0.11 (3 years) to 0.34 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Total Revenue (TTM)

ITCI:

$680.64M

HALO:

$1.51B

Gross Profit (TTM)

ITCI:

$623.67M

HALO:

$1.23B

EBITDA (TTM)

ITCI:

-$116.21M

HALO:

$980.05M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ITCI vs. HALO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ITCI

HALO
HALO Risk / Return Rank: 6666
Overall Rank
HALO Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
HALO Sortino Ratio Rank: 6666
Sortino Ratio Rank
HALO Omega Ratio Rank: 6464
Omega Ratio Rank
HALO Calmar Ratio Rank: 6565
Calmar Ratio Rank
HALO Martin Ratio Rank: 6262
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ITCI vs. HALO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intra-Cellular Therapies, Inc. (ITCI) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

ITCI vs. HALO - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


ITCIHALODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.04

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.31

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.51

Sharpe Ratio (All Time)

Calculated using the full available price history

0.23

Drawdowns

ITCI vs. HALO - Drawdown Comparison


Loading charts...

Drawdown Indicators


ITCIHALODifference

Max Drawdown

Largest peak-to-trough decline

-74.26%

Max Drawdown (1Y)

Largest decline over 1 year

-24.13%

Max Drawdown (3Y)

Largest decline over 3 years

-33.92%

Max Drawdown (5Y)

Largest decline over 5 years

-49.06%

Max Drawdown (10Y)

Largest decline over 10 years

-49.06%

Current Drawdown

Current decline from peak

-14.05%

Average Drawdown

Average peak-to-trough decline

-31.91%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.55%

Volatility

ITCI vs. HALO - Volatility Comparison


Loading charts...

Volatility by Period


ITCIHALODifference

Volatility (1M)

Calculated over the trailing 1-month period

11.55%

Volatility (6M)

Calculated over the trailing 6-month period

24.29%

Volatility (1Y)

Calculated over the trailing 1-year period

30.34%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

39.53%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

42.91%

Dividends

ITCI vs. HALO - Dividend Comparison

Neither ITCI nor HALO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ITCI vs. HALO - Financials Comparison

This section allows you to compare key financial metrics between Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M20222023202420252026
199.22M
376.71M
(ITCI) Total Revenue
(HALO) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ITCI and HALO have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for ITCI and HALO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer